SCHEMBL1875313

SCHEMBL1875313

CC(C)C(=O)NC1CCc2[nH]c3ccc(Cl)cc3c2C1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.54
HTR1B P28222 2/20 0.54
HTR1D P28221 1/20 0.54
BAZ2B Q9UIF8 2/20 0.51
SIRT1 Q96EB6 1/20 0.51
DRD2 P14416 1/20 0.48
DRD4 P21917 1/20 0.48
HTR1E P28566 1/20 0.48
HTR7 P34969 1/20 0.48
OPRM1 P35372 1/20 0.48
TMEM97 Q5BJF2 1/20 0.48
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16026808 0.87 SIRT1 (0.54) HTR1AHTR1BHTR1DBAZ2BSIRT1
SCHEMBL14624578 0.86 HTR1B (0.56) HTR1AHTR1BHTR1DBAZ2BDRD2
SCHEMBL1876695 0.86 HTR1A (0.54) HTR1AHTR1BHTR1DBAZ2BSIRT1
SCHEMBL1877210 0.86 HTR1A (0.54) HTR1AHTR1BHTR1DBAZ2BDRD2
SCHEMBL1876698 0.86 HTR1A (0.54) HTR1AHTR1BHTR1DBAZ2BSIRT1
SCHEMBL1878625 0.84 HTR1D (0.60) HTR1AHTR1BHTR1DBAZ2BSIRT1
SCHEMBL1875623 0.84 HTR1B (0.52) HTR1AHTR1BHTR1DDRD2DRD4
SCHEMBL1875621 0.84 HTR1B (0.52) HTR1AHTR1BHTR1DDRD2DRD4
SCHEMBL6530651 0.84 HTR1A (0.51) HTR1AHTR1BHTR1DBAZ2BSIRT1
SCHEMBL14624157 0.82 HTR1B (0.48) HTR1AHTR1BHTR1DDRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935722-B2 Tetrahydrocarbazole derivatives useful as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-05-03 US disclosed
EP-1902026-B1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) LILLY CO ELI (US) 2010-02-17 EP disclosed
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS CELLECTIS (FR) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS AR, SHBG, CYP17A1 HTR1A 1299/4885HTR1B 1072/4885HTR1D 1781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.